Skip to content
Pharma & Biotech Decision Intelligence

Pipeline, trials, deals, competition and market — in one decision system.

Where to invest, who to acquire, which drug will win — answered defensibly.

Seven intelligence pillars purpose-built for strategy, BD, R&D and investor teams. Move from static reports and disconnected feeds to a live, scenario-driven decision engine.

The reality: Most pharma decisions are made with fragmented data, outdated reports, and disconnected teams. This replaces that.

Built for
  • VP / Head of Strategy
  • Business Development & Licensing
  • R&D Portfolio leaders
  • Therapy Area heads
  • Competitive Intelligence
  • Pharma-focused VC / PE
Core decision

"Where should we invest, partner and compete next?"

These numbers explain why pharma strategy teams are re-tooling right now:

$126B
Pharma analytics by 2032
+16% CAGR
$4T
Pharma market 2034
IQVIA
$350B
AI value/yr in pharma
McKinsey
7
Intelligence pillars
Decision-aligned

The market is moving faster than annual reports can track. Teams that build always-on decision systems win the allocation.

Why this is different

Not a research feed. A decision system.

IQVIA, Evaluate and Cortellis give you data. We give you the system that turns it into a defensible decision.

Decisions, not reports

We don't ship another PDF. We ship the dashboard, model and pipeline that produces every future answer.

Your data + our domain models

Connects to your CRM, finance and clinical systems — overlaid with our pharma-specific intelligence layer.

Live, not stale

Live patent, deal, trial and pipeline feeds — refreshed continuously, not annually.

Built for IC, not for slides

Every output is scored, sourced and auditable. Defensible in an investment committee, not just a strategy offsite.

The decision journey

How Pharma Teams Make Strategic Decisions

Seven decisions, in sequence — from spotting where the market is growing to making the final IC call. Each step has the data, models and dashboards your team actually uses.

1 Step 1

Understand Where the Market Is Growing

Pinpoint which therapy areas, modalities and geographies are expanding — and where capital should land.

Live market sizing and segmentation across therapy areas, modalities and care settings.

Questions answered
Which therapy areas are growing fastest?
Where is geographic share shifting?
Which modalities are scaling — mRNA, gene, cell, ADC?
2 Step 2

Find Where the Real Unmet Need Is

Map disease burden, patient journey and unmet need — so you back indications with the largest underserved population.

Demand-side intelligence: epidemiology, patient flow and treatment guideline gaps.

What this enables
Where is disease burden growing?
Where do patients fall through the journey?
Which TAs have the biggest unmet need?
3 Step 3

Identify Which Drugs Will Win

Score drugs in development, project launch dates and benchmark trial success — so you bet on the right asset.

Pipeline analysis, candidate scoring and trial-readiness signals — for asset-level decisions.

Decisions you can make
Which assets are most likely to launch?
Where are the biggest pipeline risks?
Which Phase 3s are likely to succeed?
4 Step 4

Track What Competitors Are Doing — Right Now

Live competitor profiling and pipeline-vs-pipeline benchmarking — so your strategy isn't built on stale assumptions.

Real-time competitive intelligence across pipelines, pricing and innovation signals.

Questions answered
What are competitors doing right now?
Where are they overinvesting?
Where can we differentiate?
5 Step 5

Find Where Capital Is Moving

M&A, licensing and partnership intelligence — so you know who is buying, what they're paying and where to bid.

Asset-, company- and portfolio-level deal intelligence.

What this enables
Where is the next M&A wave?
What is a fair licensing deal?
Who are credible acquisition targets?
6 Step 6

Forecast Outcomes — Defensibly

Defensible base / upside / downside forecasts and scenario planning — so your IC sees ranges, not single-point optimism.

Scenario forecasting, pricing impact, technology adoption curves and prioritization frameworks.

Decisions you can make
What is the realistic forecast range?
What if pricing changes?
Which technology becomes required next?
7 Step 7

Make the Decision

The system pharma teams use to evaluate every asset, indication and BD opportunity — defensibly, repeatedly.

The decision intelligence engine: scoring, valuation, prioritization and the dashboards that operate it.

Questions answered
How do we evaluate every opportunity consistently?
Is this risk-adjusted value defensible?
Which assets do we kill?
What this looks like in practice

Sample decisions, sample outputs.

Real questions our pharma clients brought us — and what the delivered system looks like.

Portfolio Decision
The question

“Which of our 14 early-stage assets should we advance to Phase 2 — and which should we kill?”

The output

A scored asset-ranking dashboard with rNPV, competitive density, unmet-need index and a recommended fund / hold / kill action per asset.

Stack

Pipeline DB · rNPV model · Competitive-density index · Tableau dashboard

BD&L Decision
The question

“Is this licensing deal priced fairly — or are we overpaying?”

The output

A deal-comparables model benchmarking upfront, milestones and royalties against 120+ recent deals in the same TA and phase.

Stack

Deal intelligence feed · Benchmarking model · Scenario simulator

Market Entry
The question

“Should we enter the GLP-1 obesity market — and if so, where?”

The output

A market-sizing model with base / upside / downside scenarios, competitive-launch timeline overlay and geo-prioritisation matrix.

Stack

Epi data · Forecast engine · Competitive tracker · Decision matrix

Custom build

Custom Pharma Intelligence Systems

Pipeline tracking systems, clinical dashboards, deal intelligence platforms and AI forecasting tools — built on your data and decisions.

Discuss a custom build
FAQ

Frequent questions.

Is this a research service or a platform?

It’s a platform play. We deliver the dashboard, model and pipeline that produces every future answer — not just one report.

Which therapy areas do you cover?

All major TAs (oncology, cardio, immunology, CNS, rare disease, metabolic, infectious) plus emerging modalities (mRNA, cell & gene, ADCs).

Can it integrate with our existing data?

Yes — most engagements include integration with internal CRM, finance and clinical systems alongside external pipeline, deal and patent feeds.

How quickly can we start seeing decisions?

A working prototype on real data is typically 4–8 weeks. Production system follows in 8–16 weeks.

Working session

Bring one decision. We'll show you how to answer it.

Walk us through the question your team is stuck on. In one session we'll outline the data, model and dashboard that turns it into a defensible answer — and what shipping that system looks like.

Bring your decision

30-min working session · No slides · Outcome in the room